These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Walsh TJ; Hiemenz JW; Seibel NL; Perfect JR; Horwith G; Lee L; Silber JL; DiNubile MJ; Reboli A; Bow E; Lister J; Anaissie EJ Clin Infect Dis; 1998 Jun; 26(6):1383-96. PubMed ID: 9636868 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Wiley JM; Seibel NL; Walsh TJ Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Wingard JR Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244 [TBL] [Abstract][Full Text] [Related]
5. Renal effects of amphotericin B lipid complex. Luke RG; Boyle JA Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Linden P; Williams P; Chan KM Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Herbrecht R; Auvrignon A; Andrès E; Guillemain R; Suc A; Eyer D; Pailler C; Letscher-Bru V; Leverger G; Schaison G Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):77-82. PubMed ID: 11305476 [TBL] [Abstract][Full Text] [Related]
8. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Aguado JM; Lumbreras C; González-Vidal D; Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408 [TBL] [Abstract][Full Text] [Related]
9. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197 [TBL] [Abstract][Full Text] [Related]
10. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial. Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069 [TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Linden P; Lee L; Walsh TJ Pharmacotherapy; 1999 Nov; 19(11):1261-8. PubMed ID: 10555932 [TBL] [Abstract][Full Text] [Related]
12. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study. Slain D; Miller K; Khakoo R; Fisher M; Wierman T; Jozefczyk K Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292 [TBL] [Abstract][Full Text] [Related]
13. Study of renal safety in amphotericin B lipid complex-treated patients. Alexander BD; Wingard JR Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928 [TBL] [Abstract][Full Text] [Related]
14. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections. Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482 [TBL] [Abstract][Full Text] [Related]
15. The experience is CLEAR. Chandrasekar P Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248 [TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. Martino R; Subirá M; Sureda A; Sierra J J Antimicrob Chemother; 1999 Oct; 44(4):569-72. PubMed ID: 10588324 [TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Barcia JP Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667 [TBL] [Abstract][Full Text] [Related]
18. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Perfect JR Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926 [TBL] [Abstract][Full Text] [Related]
19. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Walsh TJ; Whitcomb P; Piscitelli S; Figg WD; Hill S; Chanock SJ; Jarosinski P; Gupta R; Pizzo PA Antimicrob Agents Chemother; 1997 Sep; 41(9):1944-8. PubMed ID: 9303390 [TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid complex. Rapp RP; Gubbins PO; Evans ME Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]